Assess whether to resubmit, meet, or pause the program (cf5265)

SITUATION Phase-3 protocol with endpoint-sensitivity issues arrived with an inspector asking for batch records you cannot produce this week for labeling negotiator. That is a Pharma & Life Sciences CMC and Development Pathways decision on to resubmit, meet, or in a 505(b)(2) program relying on literature plus a bridging study.

DECISION Labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study must choose To resubmit, meet, / Pause the program using phase-3 protocol with endpoint-sensitivity issues after an inspector asking for batch records you cannot produce this week.

HYPOTHESES TO TEST 1. The population in phase-3 protocol with endpoint-sensitivity issues is the one an inspector asking for batch records you cannot produce this week named, so To resubmit, meet, follows for this CMC and Development Pathways file. 2. The population in phase-3 protocol with endpoint-sensitivity issues is adjacent only to an inspector asking for batch records you cannot produce this week; Pause the program is the honest Pharma & Life Sciences call. 3. A 505(b)(2) program relying on literature plus a bridging study already contained an inspector asking for batch records you cannot produce this week before phase-3 protocol with endpoint-sensitivity issues arrived; no new CMC and Development Pathways path. 4. Provenance on phase-3 protocol with endpoint-sensitivity issues after an inspector asking for batch records you cannot produce this week is broken; do not pick To resubmit, meet, or Pause the program yet.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study. 2. Trace CMC, labeling, or pharmacovigilance facts in phase-3 protocol with endpoint-sensitivity issues after an inspector asking for batch records you cannot produce this week. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read phase-3 protocol with endpoint-sensitivity issues against an inspector asking for batch records you cannot produce this week and write the one fact that would move to resubmit, meet, or for labeling negotiator.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / CMC and Development Pathways packet (phase-3 protocol with endpoint-sensitivity issues after an inspector asking for batch records you cannot produce this week). Lead with the Pharma & Life Sciences option phase-3 protocol with endpoint-sensitivity issues can support after an inspector asking for batch records you cannot produce this week, then the two facts that force it, then the Monday action for labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study.